Overview
The Gonadotropin-Releasing Hormone Receptor (GnRHR) is a critical G protein-coupled receptor (GPCR) in the hypothalamic-pituitary-gonadal axis. It mediates the effects of GnRH to stimulate pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). First cloned in 1992, human GnRHR contains 328 amino acids and lacks intracellular C-terminal tails common to other GPCRs. Evolutionary conservation across vertebrates makes it a valuable target for both human medicine and animal husbandry applications.
Physical and Chemical Properties
As a Class A GPCR, GnRHR features seven transmembrane α-helices with extracellular N-terminus and intracellular loops that interact with G proteins. The binding pocket accommodates GnRH's conserved N-terminal pyroGlu-His sequence. The receptor exhibits rapid desensitization (tachyphylaxis) upon continuous agonist exposure, a property exploited in GnRH agonist therapies. Stability challenges include susceptibility to oxidation at methionine residues and aggregation in purification processes.
Main Applications
In clinical oncology, GnRHR antagonists like degarelix directly block receptor signaling for prostate cancer treatment, avoiding the initial testosterone surge seen with agonists. Over 60% of advanced prostate cancer cases utilize GnRHR-targeted therapy. Reproductive medicine employs GnRHR modulation for IVF protocols and treating central precocious puberty. Veterinary uses include synchronization of livestock estrus cycles, improving breeding efficiency by 20-30% in commercial operations.
Safety and Storage
Laboratory handling of recombinant GnRHR requires protease inhibitor cocktails and reducing agents to prevent degradation. Lyophilized samples should be reconstituted in degassed buffers containing 0.1% BSA. Therapeutic GnRHR ligands carry FDA boxed warnings for potential bone density loss with prolonged use. Monitoring protocols include baseline and annual DXA scans for patients on >1 year of therapy.
B2B Procurement Guide
Research buyers should verify: 1) Radioligand binding data (typically using 125I-GnRH analogs), 2) G protein coupling efficiency via GTPγS binding assays, and 3) Species compatibility with intended experimental models. For drug development partners, current Good Manufacturing Practice (cGMP)-grade receptors command 3-5x premium over research-grade materials due to stringent characterization requirements for IND submissions.